Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today ...

The copy number variant (CNV) recall was based on Illumina's DRAGEN pipeline. All variants in the GnomAD database with minor allele frequency of <1% and disease-causing variants reported in the Human ...

Trade war with China? Check. Cuts to scientific research? Check.

Illumina, Inc. ILMN recently entered into a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the ...

The combination of Illumina's Single Cell Prep, NovaSeq X Plus platform, 25B flow cell and DRAGEN analysis software creates a seamless end-to-end workflow enabling the high-throughput processing of ...

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its sequencing by extension technology, with initial ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers explore cellular behavior mapped across complex tissues. The announcement ...

BEIJING’S surprise move to blacklist Illumina has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant. While Illumina is still assessing the ...